Pages that link to "Q35912726"

The following pages link to Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model (Q35912726):

Displaying 44 items.

• Dry powder PA-824 aerosols for treatment of tuberculosis in guinea pigs (Q33768799) (← links)
• Delivery of aerosolized liposomal amikacin as a novel approach for the treatment of nontuberculous mycobacteria in an experimental model of pulmonary infection (Q34271129) (← links)
• Clofazimine: current status and future prospects (Q34633213) (← links)
• An update on the use of rifapentine for tuberculosis therapy (Q35084363) (← links)
• Antimicrobial peptides and proteins of the horse--insights into a well-armed organism (Q35232039) (← links)
• Current development and future prospects in chemotherapy of tuberculosis (Q35705874) (← links)
• Controlled-release approaches towards the chemotherapy of tuberculosis (Q36321657) (← links)
• Inhaled microparticles containing clofazimine are efficacious in treatment of experimental tuberculosis in mice (Q36558489) (← links)
• Phase I, single-dose, dose-escalating study of inhaled dry powder capreomycin: a new approach to therapy of drug-resistant tuberculosis (Q37026635) (← links)
• Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation (Q37144919) (← links)
• Delivery of antibiotics to the respiratory tract: an update (Q37564542) (← links)
• Fighting tuberculosis: old drugs, new formulations. (Q37579212) (← links)
• Preclinical models for pulmonary drug delivery (Q37620365) (← links)
• Inhaled drug delivery for tuberculosis therapy (Q37698527) (← links)
• The near future: improving the activity of rifamycins and pyrazinamide (Q37728596) (← links)
• Inhaled drug therapy for treatment of tuberculosis (Q37793595) (← links)
• Optimization of inhaled therapies for tuberculosis: The role of macrophages and dendritic cells (Q37796164) (← links)
• The interaction topology of Mycobacterium tuberculosis genes response to capreomycin and novel clues for more drug targets (Q37890323) (← links)
• Pharmaceutical aerosols for the treatment and prevention of tuberculosis (Q38042953) (← links)
• Mechanisms of absorption and elimination of drugs administered by inhalation (Q38126941) (← links)
• Nanotechnology and pulmonary delivery to overcome resistance in infectious diseases (Q38128069) (← links)
• The role of particle physico-chemical properties in pulmonary drug delivery for tuberculosis therapy. (Q38236719) (← links)
• Pharmacologic considerations in use and development of antituberculosis drugs (Q38252559) (← links)
• A review of emerging trends in the treatment of tuberculosis (Q38264545) (← links)
• Large Porous Hollow Particles: Lightweight Champions of Pulmonary Drug Delivery (Q38714479) (← links)
• The long and winding road to inhaled TB therapy: not only the bug's fault. (Q38782463) (← links)
• Phagostimulatory effect of uptake of PLGA microspheres loaded with rifampicin on alveolar macrophages (Q39519219) (← links)
• Inhaled Pyrazinoic Acid Esters for the Treatment of Tuberculosis. (Q40634015) (← links)
• Nanomaterials in the Prevention, Diagnosis, and Treatment of Mycobacterium Tuberculosis Infections. (Q41931571) (← links)
• Pharmacokinetics of sequential doses of capreomycin powder for inhalation in guinea pigs (Q42151625) (← links)
• Anti-tuberculosis activity and drug interaction with nevirapine of inhalable lipid microspheres containing rifampicin in murine model (Q43099644) (← links)
• Nanobead-based interventions for the treatment and prevention of tuberculosis (Q44117645) (← links)
• Pharmacokinetics of Ethionamide Delivered in Spray-Dried Microparticles to the Lungs of Guinea Pigs (Q46271797) (← links)
• A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection (Q46650295) (← links)
• Formulation and pharmacokinetics of self-assembled rifampicin nanoparticle systems for pulmonary delivery (Q46899549) (← links)
• Synthesis, characterization and in vitro extracellular and intracellular activity against Mycobacterium tuberculosis infection of new second-line antitubercular drug-palladium complexes (Q46959020) (← links)
• Antimicrobial properties of the equine alpha-defensin DEFA1 against bacterial horse pathogens. (Q50056787) (← links)
• Disposable Dosators for Pulmonary Insufflation of Therapeutic Agents to Small Animals. (Q50899972) (← links)
• Inhalable microparticles of nitric oxide donors induce phagosome maturation and kill Mycobacterium tuberculosis. (Q53112801) (← links)
• Efficacy of pyrazinoic acid dry powder aerosols in resolving necrotic and non-necrotic granulomas in a guinea pig model of tuberculosis (Q57095375) (← links)
• Spray Drying Strategies to Stop Tuberculosis (Q59291746) (← links)
• Tuberculosis pharmacotherapy: strategies to optimize patient care (Q83292700) (← links)
• Inhaled Antibiotics for Mycobacterial Lung Disease (Q92084477) (← links)
• Preparation and Characterization of a Dry Powder Inhaler Composed of PLGA Large Porous Particles Encapsulating Gentamicin Sulfate (Q92408518) (← links)